JPWO2021164753A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021164753A5 JPWO2021164753A5 JP2022550673A JP2022550673A JPWO2021164753A5 JP WO2021164753 A5 JPWO2021164753 A5 JP WO2021164753A5 JP 2022550673 A JP2022550673 A JP 2022550673A JP 2022550673 A JP2022550673 A JP 2022550673A JP WO2021164753 A5 JPWO2021164753 A5 JP WO2021164753A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- arginine
- cells
- genetically modified
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004475 Arginine Substances 0.000 claims description 112
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 112
- 235000009697 arginine Nutrition 0.000 claims description 112
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 85
- 108010078791 Carrier Proteins Proteins 0.000 claims description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 31
- 238000012258 culturing Methods 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 25
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 239000001963 growth medium Substances 0.000 claims description 21
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 16
- 108091006313 SLC3A2 Proteins 0.000 claims description 16
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- GGKNTGJPGZQNID-UHFFFAOYSA-N (1-$l^{1}-oxidanyl-2,2,6,6-tetramethylpiperidin-4-yl)-trimethylazanium Chemical compound CC1(C)CC([N+](C)(C)C)CC(C)(C)N1[O] GGKNTGJPGZQNID-UHFFFAOYSA-N 0.000 claims description 8
- 101710194905 ARF GTPase-activating protein GIT1 Proteins 0.000 claims description 8
- 102100035959 Cationic amino acid transporter 2 Human genes 0.000 claims description 8
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 claims description 8
- 102100021392 Cationic amino acid transporter 4 Human genes 0.000 claims description 8
- 101710195194 Cationic amino acid transporter 4 Proteins 0.000 claims description 8
- 102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 claims description 8
- 101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 8
- 102100038204 Large neutral amino acids transporter small subunit 1 Human genes 0.000 claims description 8
- 102100038235 Large neutral amino acids transporter small subunit 2 Human genes 0.000 claims description 8
- 108091006231 SLC7A2 Proteins 0.000 claims description 8
- 108091006230 SLC7A3 Proteins 0.000 claims description 8
- 108091006232 SLC7A5 Proteins 0.000 claims description 8
- 108091006238 SLC7A8 Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 230000004068 intracellular signaling Effects 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 230000037452 priming Effects 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979805P | 2020-02-21 | 2020-02-21 | |
| US62/979,805 | 2020-02-21 | ||
| PCT/CN2021/077002 WO2021164753A1 (fr) | 2020-02-21 | 2021-02-20 | Procédés et compositions pour la modulation des niveaux d'arginine dans les cellules immunitaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515806A JP2023515806A (ja) | 2023-04-14 |
| JPWO2021164753A5 true JPWO2021164753A5 (fr) | 2024-02-29 |
Family
ID=77390457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550673A Pending JP2023515806A (ja) | 2020-02-21 | 2021-02-20 | 免疫細胞においてアルギニン濃度をモジュレートするための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265386A1 (fr) |
| EP (1) | EP4107254A4 (fr) |
| JP (1) | JP2023515806A (fr) |
| KR (1) | KR20220157396A (fr) |
| CN (1) | CN115427553A (fr) |
| AR (1) | AR121392A1 (fr) |
| AU (1) | AU2021223138A1 (fr) |
| BR (1) | BR112022016571A2 (fr) |
| CA (1) | CA3171901A1 (fr) |
| IL (1) | IL295606A (fr) |
| MX (1) | MX2022010280A (fr) |
| TW (1) | TW202144569A (fr) |
| WO (1) | WO2021164753A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202018554D0 (en) * | 2020-11-25 | 2021-01-06 | Cancer Research Tech Ltd | Nucleic acid constructs and cells |
| CN114788870B (zh) * | 2022-04-29 | 2023-06-06 | 浙江大学 | 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2939646T3 (es) * | 2016-10-13 | 2023-04-25 | Juno Therapeutics Inc | Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano |
| GB201701332D0 (en) * | 2017-01-26 | 2017-03-15 | Tc Biopharm Ltd | Immune cells with modified metabolism and their use thereof |
| GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
-
2021
- 2021-02-20 JP JP2022550673A patent/JP2023515806A/ja active Pending
- 2021-02-20 BR BR112022016571A patent/BR112022016571A2/pt unknown
- 2021-02-20 MX MX2022010280A patent/MX2022010280A/es unknown
- 2021-02-20 CA CA3171901A patent/CA3171901A1/fr active Pending
- 2021-02-20 US US17/800,958 patent/US20230265386A1/en active Pending
- 2021-02-20 AU AU2021223138A patent/AU2021223138A1/en active Pending
- 2021-02-20 WO PCT/CN2021/077002 patent/WO2021164753A1/fr unknown
- 2021-02-20 EP EP21757810.3A patent/EP4107254A4/fr active Pending
- 2021-02-20 IL IL295606A patent/IL295606A/en unknown
- 2021-02-20 CN CN202180026648.4A patent/CN115427553A/zh active Pending
- 2021-02-20 KR KR1020227032553A patent/KR20220157396A/ko unknown
- 2021-02-20 TW TW110105930A patent/TW202144569A/zh unknown
- 2021-02-22 AR ARP210100448A patent/AR121392A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200171151A1 (en) | Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator | |
| US20190093085A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| JP7546925B2 (ja) | 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用 | |
| JP6580555B2 (ja) | 増強された養子細胞療法 | |
| EP0259212B1 (fr) | Expression d'un antigène spécifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement préventif ou curatif de la tumeur correspondante | |
| US20230137548A1 (en) | Neural stem cell-mediated cancer treatment | |
| US20160296612A1 (en) | Methods and compositions for treating or preventing cancer | |
| HU230364B1 (hu) | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására | |
| JPH06508025A (ja) | 癌胎児性抗原を発現する組換えウイルスとその使用方法 | |
| US10849964B2 (en) | Methods and materials for treating cancer | |
| US20240325510A1 (en) | Novel anti-cancer vaccine composition and a method of vaccination using the same | |
| FR2757169A1 (fr) | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin | |
| US11951182B2 (en) | Combination therapy for treatment of thoracic cancer using Ad-REIC/Dkk-3 and a checkpoint inhibitor | |
| JP2001524934A (ja) | 遺伝子治療ウイルスベクターの投与に対して哺乳類罹患動物を寛容化する方法 | |
| JPWO2021164753A5 (fr) | ||
| CN115975056A (zh) | 利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞 | |
| Lin et al. | Applications of Virus Vector–Mediated Gene Therapy in China | |
| WO2022230971A1 (fr) | Cellule vecteur adjuvante artificielle capable d'induire une réponse immunitaire au coronavirus, composition pharmaceutique contenant ladite cellule, et applications d'utilisation de ladite cellule et de ladite composition pharmaceutique | |
| JP7572102B2 (ja) | 腫瘍溶解性遺伝子改変麻疹ウイルスの新規用途 | |
| WO2004110485A1 (fr) | Matieres et procedes pour vaccination amelioree | |
| WO2023176938A1 (fr) | Nouvelle utilisation du virus oncolytique de la rougeole génétiquement modifié | |
| WO2022011651A1 (fr) | Procédé d'immunothérapie par administration ciblée de chimiokines et de cytokines par une cellule souche mésenchymateuse | |
| KR20230137369A (ko) | 면역 내성 유도를 위한 조성물 및 유전자 치료에서의용도 | |
| JP2023554319A (ja) | がんを治療するための方法及び材料 | |
| CN114560916A (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽KLLEQWNLV及其应用 |